Economics of dementia and pharmacoeconomics of dementia therapy

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 1, 2005, Pages 39-49

  Fillit, Howard ^a   Hill, Jerrold ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Dementia; Donepezil; Galantamine; Memantine; Pharmacoeconomics; Rivastigmine; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; TACRINE;

AGED; ARTICLE; CAREGIVER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ECONOMIC EVALUATION; FAMILY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INSTITUTIONALIZATION; MANAGED CARE; MEDLINE; PATIENT SELECTION; PRIORITY JOURNAL; SENILE DEMENTIA; SOCIETY;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST OF ILLNESS; DEMENTIA; ECONOMICS, PHARMACEUTICAL; HUMANS; INSTITUTIONALIZATION; MEDLINE; MODELS, ECONOMIC; NOOTROPIC AGENTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 23744487978     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2005.03.005     Document Type: Article

References (76)

1. Gwyther L.P. Social issues of the Alzheimer's patient and family Am J Med 104 1998 17S-21S
2. Knapp M. Wilkinson D. Wigglesworth R. The economic consequences of Alzheimer's disease in the context of new drug developments Int J Geriatr Psychiatry 13 1998 531-543
3. Kirschstein R. Disease-specific estimates of direct and indirect costs of illness and NIH support. Fiscal year 2000 update Accessed July 2, 2002 National Institutes of Health Available at: http://ospp.od.nih.gov/ecostudies/COIreportweb.htm
4. Fillit H. Geldmacher D.S. Welter R.T. et al. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias J Am Geriatr Soc 50 2002 1871-1878
5. Winblad B. Jelic V. Long-term treatment of Alzheimer disease: Efficacy and safety of acetylcholinesterase inhibitors Alzheimer Dis Assoc Disord 18 Suppl 1 2004 S2-S8
6. Gracon S.I. Knapp M.J. Berghoff W.G. et al. Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience Alzheimer Dis Assoc Disord 12 1998 93-101
7. Black S. Roman G.C. Geldmacher D.S. et al. for the Donepezil 307 Vascular Dementia Study Group Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized,placebo-controlled clinical trial Stroke 34 2003 2323-2330
8. Wilkinson D. Doody R. Helme R. et al. Donepezil 308 Study Group Donepezil in vascular dementia: A randomized, placebo-controlled study Neurology 61 2003 479-486
9. Moretti R. Torre P. Antonello R.M. et al. Rivastigmine in subcortical vascular dementia: An open 22-month study J Neurol Sci 203-204 2002 141-146
10. Moretti R. Torre P. Antonello R.M. et al. Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 12-month study in 208 patients Am J Alzheimers Dis Other Demen 18 2003 265-272
11. Querfurth H.W. Allam G.J. Geffroy M.A. et al. Acetylcholinesterase inhibition in dementia with Lewy bodies: Results of a prospective pilot trial Dement Geriatr Cogn Disord 11 2000 314-321
12. Samuel W. Caligiuri M. Galasko D. et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: A preliminary study Int J Geriatr Psychiatry 15 2000 794-802
13. Maclean L.E. Collins C.C. Byrne E.J. Dementia with Lewy bodies treated with rivastigmine: Effects on cognition, neuropsychiatric symptoms, and sleep Int Psychogeriatr 13 2001 277-288
14. Grace J. Daniel S. Stevens T. et al. Long-term use of rivastigmine in patients with dementia with Lewy bodies: An op en-label trial Int Psychogeriatr 13 2001 199-205
15. Wesnes K.A. McKeith I.G. Ferrara R. et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the cognitivedrug research computerised assessment system Dement Geriatr Cogn Disord 13 2002 183-192
16. Erkinjuntti T. Kurz A. Gauthier S. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial Lancet 359 2002 1283-1290
17. Erkinjuntti T. Kurz A. Small G.W. et al. for the GALINT-6 Study Group An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia Clin Ther 25 2003 1765-1782 [published correction appears in Clin Ther. 2003;25:2336]
18. Reisberg B. Doody R. Stoffler A. et al. for the Memantine Study Group Memantine in moderate-tosevere Alzheimer's disease N Engl J Med 348 2003 1333-1341
19. Doody R.S. Stevens J.C. Beck C. et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 2001 1154-1166
20. Sano M. Ernesto C. Thomas R.G. et al. Alzheimer's Disease Cooperative Study A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease N Engl J Med 336 1997 1216-1222
21. Rogers S.L. Farlow M.R. Doody R.S. et al. for the Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology 50 1998 136-145
22. Burns A. Rossor M. Hecker J. et al. The effects of donepezil in Alzheimer's disease results from a multinational trial Dement Geriatr Cogn Disord 10 1999 237-244
23. Corey-Bloom J. Anand R. Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease Int J Geriatr Psychopharmacol 1 1998 55-65
24. Rockwood K. Mintzer J. Truyen L. et al. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial J Neurol Neurosurg Psychiatry 71 2001 589-595
25. Wilcock G.K. Lilienfeld S. Gaens E. for the Galantamine International-1 Study Group Efficacy and safety of galantamine in patients with mild to moderate Alz heimer's disease: Multicentre randomised controlled trial BMJ 321 2000 1445-1449 [published correction appears in BMJ. 2001;322:405]
26. Feldman H. Gauthier S. Hecker J. et al. for the Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease Neurology 57 2001 613-620 [published correction appears in Neurology. 2001;57:2153]
27. Winblad B. Engedal K. Soininen H. Donepezil et al. for the Nordic Study Group A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 97 2001 489-495
28. Tariot P.N. Solomon P.R. Morris J.C. Galantamine et al. for the USA-10 Study Group A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology 54 2000 2269-2276
29. Rogers S.L. Doody R.S. Mohs R.C. Friedhoff L.T. for the Donepezil Study Group Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study Arch Intern Med 158 1998 1021-1031
30. Roster M. Anand R. Cicin-Sain A. et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial BMJ 318 1999 633-638 [published correction appears in BMJ. 2001; 322:1456]
31. Mohs R.C. Doody R.S. Morris J.C. for the "312" Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients Neurology 57 2001 481-488 [published correction appears in Neurology. 2001;57: 1942]
32. Gauthier S. Feldman H. Hecker J. Donepezil et al. for the MSAD Study Investigators Group Efficacy of donepezil on behavioral symptoms in patients with mod erate to severe Alzheimer's disease Int Psychogeriatr 14 2002 389-404
33. Boustani M. Peterson B. Hanson L. et al. for the US Preventive Services Task Force Screening for dementia in primary care: A summary of the evidence for the US Preventive Services Task Force Ann Intern Med 138 2003 927-937
34. Feldman H. Gauthier S. Hecker J. et al. Donepezil shows benefits in patients with moderate to severe Alzheimer's disease (AD), independent of baseline dementia severity J Am Geriatr Soc 51 2002 552
35. Trinh N.H. Hoblyn J. Mohanty S. Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis JAMA 289 2003 210-216
36. Leon J. Cheng C.K. Neumann P.J. Alzheimer's disease care: Costs and potential savings Health Aff (Millwood) 17 1998 206-216
37. Fillit H. Hill J. The costs of vascular dementia: A comparison with Alzheimer's disease J Neurol Sci 203-204 2002 35-39
38. Gutterman E.M. Markowitz J.S. Lewis B. Fillit H.M. Cost of Alzheimer's disease and related dementia in managed-Medicare J Am Geriatr Soc 47 1999 1065-1071
39. Hill J.W. Futterman R. Duttagupta S. et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare Neurology 58 2002 62-70
40. Martin B.C. Ricci J.F. Kotzan J.A. et al. The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients Alzheimer Dis Assoc Disord 14 2000 151-159
41. Menzin J. Lang K. Friedman M. et al. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995 Am J Geriatr Psychiatry 7 1999 300-308
42. Available at: Chronic Care Networks for Alzheimer's Disease. CCN/AD interim evaluation findings Accessed October 12, 2004 http://www.nccconline.org/pdf/CCNADInterimResults11-02.pdf
43. Wimo A. Winblad B. Engedal K. et al. for the Donepezil Nordic Study Group An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial Dement Geriatr Cogn Disord 15 2003 44-54 [published correction appears in Dement Geriatr Cogn Disord. 2003;16: 102]
44. Wimo A. Winblad B. Stoffler A. et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease Pharmaco Economics 21 2003 327-340
45. Feldman H. Gauthier S. Hecker J. et al. for the Donepezil MSAD Study Investigators Group Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden J Am Geriatr Soc 51 2003 737-744 [published correction appears in J Am Geriatr Soc.2003;51:1331]
46. Sano M. Wilcock G.K. van Baelen B. Kavanagh S. The effects of galantamine treatment on caregiver time in Alzheimer's disease Int J Geriatr Psychiatry 18 2003 942-950
47. Kaufer D.I. Sadik K. Galantamine reduces caregiver time spent providing assistance to individuals with mild-tomoderate Alzheimer's disease Am J Geriatr Psychiatry 10 Suppl 1 2002 84-85
48. Fillit H.M. Gutterman E.M. Brooks R.L. Impact of donepezil on caregiving burden for patients with Alzheimer's disease Int Psychogeriatr 12 2000 389-401
49. Knopman D. Schneider L. Davis K. et al. for the Tacrine Study Group Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality Neurology 47 1996 166-177
50. Lopez O.L. Becker J.T. Wisniewski S. et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease J Neurol Neurosurg Psychiatry 72 2002 310-314
51. Geldmacher D.S. Provenzano G. McRae T. et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease J Am Geriatr Soc 51 2003 937-944
52. Brookmeyer R. Gray S. Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337-1342
53. Courtney C. Farrell D. Gray R. et al. for the AD2000 Collaborative Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Ran domized double-blind trial Lancet 363 2004 2105-2115
54. Neumann P.J. Hermann R.C. Kunntz K.M. et al. Costeffectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease Neurology 52 1999 1138-1145
55. O'Brien B.J. Goeree R. Hux M. et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada J Am Geriatr Soc 47 1999 570-578
56. Hauber A.B. Gnanasakthy A. Snyder E.H. et al. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine PharmacoEconomics 17 2000 351-360
57. Getsios D. Caro J.J. Caro G. Ishak K. for the AHEAD Study Group Assessment of health economics in Alzheimer's disease (AHEAD): Galantamine treatment in Canada Neurology 57 2001 972-978
58. Migliaccio-Walle K. Getsios D. Caro J.J. et al. for the AHEAD Study Group Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States Clin Ther 25 2003 1806-1825
59. Hill J.W. Futterman R. Mastey V. Fillit H. The effect of donepezil therapy on health costs in a Medicare managed care plan Manag Care Interface 15 2002 63-70
60. Fillit H. Hill J.W. Futterman R. Health care utilization and costs of Alzheimer's disease: The role of co-morbid conditions, disease stage, and pharmacotherapy Pam Med 34 2002 528-535
61. Abstract Cummings J. Duttagupta S. Wade S. et al. Cost savings associated with use of donepezil in managed care Am J Geriatr Psychiatry 9 Suppl 1 2001 53
62. Doody R.S. Geldmacher D.S. Gordon B. et al. for the Donepezil Study Group Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease Arch Neurol 58 2001 427-433
63. Caro J.J. Salas M. Ward A. et al. for the AHEAD Study Group Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands Dement Geriatr Cogn Disord 14 2002 84-89
64. Hauber A.B. Gnanasakthy A. Mauskopf J.A. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine Clin Ther 22 2000 439-451
65. Ernst R.L. Hay J.W. Fenn C. et al. Cognitive function and the costs of Alzheimer disease. An exploratory study Arch Neurol 54 1997 687-693
66. Shah S. Keohane D. Strunk B. Retrospective analysis of characteristics in long-term care residents with Alzheimer's disease continuing versus discontinuing do nepezil treatment J Am Geriatr Soc 2004 Abstract. In press
67. Sloane P.D. Zimmerman S. Suchindran C. et al. The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances Annu Rev Public Health 23 2002 213-231
68. Langa K.M. Chernew M.E. Kabeto M.U. et al, National estimates of the quantity and cost of informal caregiving for the elderly with dementia J Gen Intern Med 16 2001 770-778
69. Hux M.J. O'Brien B.J. Iskedjian M. et al. Relation between severity of Alzheimer's disease and costs of caring CMAJ 159 1998 457-465
70. Leon J. Neumann P.J. The cost of Alzheimer's disease in managed care: A cross-sectional study Am J Manag Care 5 1999 867-877
71. Moore M.J. Zhu C.W. Clipp E.C. Informal costs of dementia care: Estimates from the National Longitudinal Caregiver Study J Gerontol B Psychol Sci Soc Sci 56 2001 S219-S228
72. Murman D.L. Chen Q. Powell M.C. et al. The incremental direct costs associated with behavioral symptoms in AD Neurology 59 2002 1721-1729
73. Hay J.W. Ernst R.L. The economic costs of Alzheimer's disease Am J Public Health 77 1987 1169-1175
74. Small G.W. McDonnell D.D. Brooks R.L. Papadopoulos G. The impact of symptom severity on the cost of Alzheimer's disease J Am Geriatr Soc 50 2002 321-327
75. Stommel M. Collins C.E. Given B.A. The costs of family contributions to the care of persons with dementia Gerontologist 34 1994 199-205
76. Njegovan V. Hing M.M. Mitchell S.L. Molnar F.J. The hierarchy of functional loss associated with cognitive decline in older persons J Gerontol A Biol Sci Med Sci 56 2001 M638-M643